iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

AstraZeneca Pharma Q3 PAT falls 45% YoY to Rs 11 cr

9 Feb 2022 , 08:46 AM

Net sales grew by marginal 0.1% year on year to Rs 200.53 crore in Q3 FY22 as compared to Rs 200.25 crore posted in Q3 FY21. Profit before tax fell 42.5% to Rs 16.26 crore in Q3 FY22 over Q3 FY21.

The drug makers total expenditure spiked 9.6% to Rs 185.86 crore in Q3 FY22 from Rs 169.51 crore posted in the corresponding period last year.

In last three months, shares of AstraZeneca have fallen 7.9% as compared to a 4.4% decline in benchmark Nifty 50 index.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease.

AstraZeneca ended 0.56% lower at Rs 2,767.60 on Tuesday.

Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.